MAP2K7 and neoplasm: This effect can be limited by the combination with a MEK inhibitor [14], nevertheless tumor escape after 2 months of treatment with this combination suggests that in MM cells carrying an activating mutation of a RAS gene, MEK inhibition is insufficient to block the excessive oncogenic activation of the MAPK pathway due to CRAF trans‐activation.